| Literature DB >> 35244811 |
Pedro L Valenzuela1,2, Gonzalo Saco-Ledo2, Alejandro Lucia1,2, Carmen Fiuza-Luces3, Alejandro Santos-Lozano2,4, Javier S Morales5, Adrián Castillo-García6, Richard J Simpson7,8,9.
Abstract
BACKGROUND: Exercise training can positively impact the immune system and particularly natural killer (NK) cells, at least in healthy people. This effect would be of relevance in the context of cancer given the prominent role of these cells in antitumor immunity. In this systematic review and meta-analysis, we aimed to summarize current evidence on the effects of exercise training on the levels and function of NK cells in cancer survivors (i.e., from the time of diagnosis until the end of life).Entities:
Keywords: Cytotoxic activity; Immune function; Immune system; Immunity; Oncology; Physical activity; Training
Year: 2022 PMID: 35244811 PMCID: PMC8897541 DOI: 10.1186/s40798-022-00419-w
Source DB: PubMed Journal: Sports Med Open ISSN: 2198-9761
Fig. 1Flowchart of literature search. WoS Web of Science
Main characteristics of the included studies
| Study | Cancer and treatment | Study groups | Exercise training intervention | Technique | Variable | Results (main exercise training effects) |
|---|---|---|---|---|---|---|
| Fairey et al. [ | Stage I to IIIB breast cancer | Exercise: | Modality: supervised aerobic training | Flow cytometry | Percentage of NK cells in PBMCs | ↔ NK cells |
| Completed surgery, radiotherapy and/or chemotherapy (14 ± 6 months prior to enrollment) with/without tamoxifen or anastrozole therapy | Length and frequency: 15 weeks, 3 days/week | 51Cr release assay K562 as the target cell | NKCA in PBMCs: percentage of 51Cr release and PBMCs corrected to a per cell basis (lytic units/103, number of effector cells required to cause 30% lysis of target cells) | ↑ NKCA at all E:T ratios | ||
| Control: | Duration: 15 – 35 min | E:T ratios = 50:1, 25:1, 12.5:1, 6.25:1, 3.125:1 | ||||
| Intensity: ~70–75% VO2peak | ||||||
| Fiuza-Luces et al. [ | Extracranial solid tumors | Exercise: | Modality: supervised aerobic and resistance training | Flow cytometry | Absolute number and percentage of NK cells, NK cell subsets (NKbright and NKdim) and NK cells expressing different activating or inhibitory receptors in total blood | ↔ NK cell |
| During neoadjuvant chemotherapy | Control: | Length and frequency: the neoadjuvant chemotherapy period (19 ± 2 weeks), 3 days/week in gym sessions or 5 days/week in ward sessions | ↔ NK cell receptors | |||
| Europium-TDA release assay | NKCA in PBMCs: percentage of K562 lysis | ↔ NKCA | ||||
| Duration: 30 min of aerobic training; 30 min of resistance training | K562 as the target cell | |||||
| E:T ratios = 8:1. 4:1, 2:1, 1:1 | ||||||
| Intensity: 60–70% HRmax (aerobic training); intensity progressively increased (resistance training) | ||||||
| Glass et al. [ | Solid tumors (mainly breast cancer) | Exercise: | Modality: supervised aerobic training | Flow cytometry | Percentage of NK cells in PBMCs | ↔ NK cells |
| During cytotoxic therapy and synthetic erythropoietin therapy | Length and frequency: 12 weeks, 3 days/week | |||||
| Control: | Duration: 20–45 min | |||||
| Intensity: 55–100% VO2peak | ||||||
| Hagstrom et al. [ | Stage I to IIIA breast cancer | Exercise: | Modality: supervised resistance training | Flow cytometry | Percentage of NK cells in total blood | ↔ NK cells |
| Completed surgery, radiotherapy and/or chemotherapy (11.5 months average prior to enrollment) with/without hormone therapy | Length and frequency: 16 weeks, 3 days/week | Flow cytometry | Percentage of functional markers (granzyme B and perforin) of NKCA in total blood | ↔ granzyme B and perforin expression in NK cells | ||
| Control: | Duration: 60 min | Flow cytometry | Percentage of NK cell intracellular cytokine (TNFɑ and IFNγ) production in total blood | ↓ NK cell expression of TNFɑ | ||
| Intensity: 8-RM | ||||||
| Kaushik et al. [ | Prostate cancer | Exercise | Modality: supervised Hatha yoga | Flow cytometry | Frequency and absolute number of NK cells and CD56bright and CD56dim NK cells in preactivated PBMCs | ↔ NK cells |
| Perioperative (radical prostatectomy) period | Control | Length and frequency: 6 weeks preoperatively + 6 weeks starting 3–6 weeks postoperatively, 2 days/week | Flow cytometry | Cytokine response in NK cells from preactivated PBMCs | ↑ Fc receptor III production and IFN-γ expression in NK cells | |
| Duration: 60 min | ||||||
| Intensity: adapted to patients’ comfort level | ||||||
| Ligibel et al. [ | Breast cancer | Exercise: | Modality: supervised and unsupervised aerobic/resistance training | Immunohistochemistry | Percentage of NK cells in tumor tissue | ↔ NK cells |
| Preoperative breast surgery | Length and frequency: mean of 29.3 days, 2 days/week | |||||
| Control: | Duration: 180 min of aerobic training and 40 min of resistance training | |||||
| Intensity: moderate | ||||||
| Liu et al. [ | Stages I to IIIB non-small cell lung cancer | Exercise: | Modality: supervised Tai Chi | Flow cytometry | Percentage of NK cells in total blood | ↑ NK cells |
| Post-surgery (≥ 2 years prior to enrollment) | Length and frequency: 16 weeks, 3 days/week | Cell viability assay | NKCA in PBMCs: tumor cell viability assay | ↑ NKCA at 25:1 and 50:1 E:T ratios | ||
| Control: | Duration: 60 min | A549 as the target cell | ||||
| Intensity: moderate | E:T cell ratios = 50:1, 25:1, 12.5:1 | |||||
| Mohamady et al. [ | Breast cancer | Exercise: | Modality: supervised and home-based training. Proprioceptive neuromuscular facilitation, resistance training and aerobic training | Flow cytometry | Number of NK cells in total blood | ↑ NK cells |
| Post-surgery | Control: | Length and frequency: 12 weeks, twice a day, 3 – 7 days/week | ||||
| Duration: 30 min | ||||||
| Intensity: moderate | ||||||
| Na et al. [ | Stomach cancer | Exercise: | Modality: supervised mobility exercises and resistance training (in bed) and supervised aerobic training (ambulatory setting) | 51Cr release assay | NKCA in PBMCs: percentage of specific 51Cr release | ↑ NKCA |
| Post-surgery | Control: | Length and frequency: 2 weeks. Exercise in bed: 3 times a day. Ambulatory setting: 5 days/week, twice a day | K562 as the target cell | |||
| Duration: 30 min | E:T ratio = 50:1 | |||||
| Intensity: 60% HRmax (aerobic training); isometric (resistance training) | ||||||
| Nieman et al. [ | Breast cancer | Exercise: | Modality: supervised aerobic and resistance training | Flow cytometry | Percentage of NK cells in total blood | ↔ NK cells |
| Completed surgery, chemotherapy and/or radiotherapy within the previous 3.0 ± 1.2 years | Length and frequency: 8 weeks, 3 days/week | 51Cr release assay | NKCA in PBMCs: percentage of 51Cr release | ↔ NKCA | ||
| Control: | Duration: 30 min of aerobic training and 30 min of resistance training | K562 as the target cell | ||||
| Intensity: 75% HRmax (aerobic training); intensity progressively increased (resistance training) | E:T ratios = 40:1, 20:1 | |||||
| Sagarra-Romero et al. [ | Stage I and II breast cancer | Exercise: | Modality: supervised aerobic and resistance training | N/R | Percentage of NK cells in total blood | ↔ NK cells |
| Undergone surgery and receiving adjuvant chemotherapy | Length and frequency: 18–22 weeks, 3 days/week | |||||
| Control: | Duration: 45 min; 20 min of aerobic training and 25 min of resistance training | |||||
| Intensity: 60–70% VO2peak (aerobic training) and N/R for resistance training | ||||||
| Schmidt et al. [ | Primary moderate- or high-risk breast cancer | Strength exercise: | Modality: supervised aerobic or resistance training | Flow cytometry | Absolute number of NK cells in total blood | ↔ NK cells |
| From the initiation of chemotherapy to the end of epirubicin or cyclophosphamide therapy | Aerobic exercise: | Length and frequency: 12 weeks, twice weekly | ||||
| Duration: 60 min | ||||||
| Control: | Intensity: Borg scale of 11–14 (aerobic training) and 50% of the maximum weight with increments based on Borg scale (resistance training) | |||||
| Toffoli et al. [ | Resectable colon (stage II/III) or breast cancer (stage I/II/III) | Exercise: | Modality: supervised aerobic and resistance training | Flow cytometry | NK cell subsets (NKbright and NKdim) and NK cells expressing different activating or inhibitory receptors in total blood | ↑ NKp46 (activating receptor) on CD56dim CD16+ NK cells |
| During neoadjuvant chemotherapy | Control: | Length and frequency: during the first 9–12 weeks or treatment, twice weekly | NK cell degranulation and cytotoxicity assay by flow cytometry | NK cell degranulation in monocyte-depleted PBMCs: percentage of CD107a+ NK cells | ↔ NK cell degranulation | |
| Duration: 60 min | A431 as the target cell | |||||
| Intensity: moderate to high | E:T ratio = 4:1 | NKCA in monocyte-depleted PBMCs: relative percentage of cytotoxicity (of living tumor cells) | ↔ NKCA |
Cr chromium, E:T effector-to-target, HRmax maximum heart rate, IFNγ interferon gamma, NK natural killer, NKCA,NK cell cytotoxic activity, N/R not reported, PBMCs peripheral blood mononuclear cells, RCT randomized controlled trial, RM repetition maximum, TDA 2,2′:6′, 2″-terpyridine-6,6″-dicarboxylic acid, TNFα tumor necrosis factor-alpha, VO peak oxygen consumption. Symbols: ↑ increase, ↔ no change, ↓ decrease
Methodological quality of the included studies
| Authors (year) | Items | Total score* | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ||
| Fairey et al. [ | + | + | + | + | − | − | + | + | + | + | + | 8 |
| Fiuza-Luces et al. [ | + | + | − | + | − | − | + | − | − | + | + | 5 |
| Glass et al. [ | + | + | + | + | − | − | + | − | + | + | + | 7 |
| Hagstrom et al. [ | + | + | − | + | − | − | + | + | + | + | + | 7 |
| Kaushik et al. [ | + | + | − | + | − | − | − | + | − | + | + | 5 |
| Ligibel et al. [ | + | + | − | + | − | − | + | − | + | + | + | 6 |
| Liu et al. [ | + | + | + | + | − | − | − | + | − | + | + | 6 |
| Mohamady et al. [ | + | + | − | − | − | − | − | + | − | + | + | 4 |
| Na et al. [ | + | + | − | + | − | − | − | + | − | + | + | 5 |
| Nieman et al. [ | + | + | − | + | − | − | − | + | − | + | + | 5 |
| Sagarra-Romero et al. [ | + | + | − | + | − | − | − | − | − | + | + | 4 |
| Schmidt et al. [ | + | + | + | + | − | − | + | − | − | + | + | 6 |
| Toffoli et al. [ | + | + | − | + | − | − | − | − | − | + | + | 4 |
Column numbers correspond to the following criteria on the PEDro scale: 1—eligibility criteria were specified; 2—subjects were randomly allocated to groups; 3—allocation was concealed; 4—groups were similar at baseline; 5—subjects were blinded; 6—therapists who administered the treatment were blinded; 7—assessors were blinded; 8—measures of key; outcomes were obtained from more than 85% of subjects; 9—data were analyzed by intention to treat; 10—statistical comparisons between groups were conducted; 11—point measures and measures of variability were provided. +indicates the criterion was clearly satisfied; −indicates that it was not. * A total score out of 10 is determined from a number of criteria that are satisfied, except that scale item 1 is not used to generate the total score
Fig. 2Effects of exercise training interventions on natural killer cell number (expressed as percentage of total number of circulating lymphocytes or peripheral blood mononuclear cells). CI confidence interval, MD mean difference
Fig. 3Research gaps and methodological issues that should be considered in future studies assessing the potential effects of exercise on natural killer (NK) cells in the context of cancer